A 12 May 2023 inspection of an Intas Pharmaceuticals Ltd. plant in Sarkhej, a suburb of Ahmedabad, India, has uncovered another stunning display of data manipulation at the firm, according to the US Food and Drug Administration’s 15-observation, 29-page Form 483 report of inspectional observations.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?